

# **Clinical data science in action: data-driven decisions in late-stage drug development**

Boris Grimm, Stefan Döring (Boehringer Ingelheim Pharma GmbH & Co. KG)

## **Abstract:**

The development of new drugs is a highly complex, data-intensive process. In this presentation, we will provide insight into the role of data science and biostatistics in late-stage clinical development at Boehringer Ingelheim, one of the world's leading research-based pharmaceutical companies.

Following a brief introduction to Boehringer Ingelheim and the Biostatistics & Data Sciences (BDS) organization, we will demonstrate how clinical data from Phase II and Phase III studies are systematically planned, analyzed, and interpreted. The focus will be on how statistical methods, modern data science approaches, and interdisciplinary collaboration contribute to making robust decisions regarding the efficacy, safety, and benefits of new therapies.

It will become clear that clinical data science goes far beyond traditional statistics and increasingly integrates methods from machine learning, data engineering, and visual analytics.